There is a growing appreciation by cancer researchers of the influence that the microenvironment has on tumor growth. The late Judah Folkman suggested that "the interplay between tumor cells and endothelial cells constitutes a highly integrated ecosystem." He proposed that because tumors are dependent on the formation of new blood vessels (angiogenesis) for growth, targeting blood vessels in the surrounding tumor microenvironment may prevent tumor progression (Folkman, 1972) . This concept of the tumor "ecosystem" has now been extended beyond the vasculature to include many diverse facets of the microenvironment, such as the immune system (van Kempen et al., 2003) , stromal fibroblasts, and the extracellular matrix, including most recently the concept of the cancer stem cell niche (Sneddon and Werb, 2007) . Underlying this interest in the tumor microenvironment is the notion that tumor cells under certain conditions cannot grow or survive in the absence of support from the microenvironment. Indeed, the microenvironment may even drive tumor development. Although genetic and epigenetic changes may be selected for in cells of the microenvironment, their relative genomic stability compared to primary cancer cells may provide a therapeutic target (Kenny et al., 2007) with a lower probability of drug resistance developing. In this issue of Cell, Yang et al. (2008) present an elegant use of genetically engineered mouse models to . Aging stroma may be more permissive for tumor growth compared with "younger" stroma. In the case of genetic diseases such as neurofibromatosis, the stroma harbors a pre-existing inherited mutation. dissect the role of inflammation in the tumor microenvironment. On the basis of their findings, Yang and colleagues were able to treat a young patient with life-threatening complications of neurofibromatosis type 1 (NF1) in an exciting bench-to-bedside success story.
Previously, these authors demonstrated that formation of benign Schwann cell-derived tumors (neurofibromas) requires biallelic loss of the Nf1 gene in peripheral nerve Schwann cells and loss of one copy of Nf1 in the surrounding stroma. Neurofibromas are often infiltrated by mast cells, and these authors showed signaling between Nf1 mutant Schwann cells and Nf1 heterozygous mast cells. In their new study, Yang et al. now show in vivo that Nf1 heterozygous hematopoietic cells derived from bone marrow migrate to developing neurofibromas and are required for neurofibroma growth. Tumor formation required the activity of the c-kit receptor tyrosine kinase, which is known to promote mast cell migration, proliferation, and survival. Taken together with the known links between mast cells and neurofibromas, the findings of Yang et al. implicate c-kit-dependent mast cells in the tumor microenvironment as mediators of tumorigenesis. Interestingly, the microenvironment in this case is not "normal" as wild-type mast cells do not support tumor growth. Only Nf1 heterozygous mast cells with hypersensitivity to migratory stimuli can support tumor growth. Other studies have also demonstrated that the tumor stroma is different from normal stroma. For example, the vasculature associated with colorectal cancer (St Croix et al., 2000) and the fibroblasts in basal cell carcinoma (Sneddon and Werb, 2007) both differ from their normal counterparts. However, it is not clear whether these changes in the stroma are the cause or result of tumor formation.
As cancer research diverges from "a reductionist focus" on cancer cell mutations (Hanahan and Weinberg, 2000) , there is a growing appreciation that intrinsic clonal evolution of the cancer cell does not occur in isolation. Rather, a variety of local cell populations can be modulated by environmental and age-related alterations as well as by emerging biological changes in associated cancer cells to produce the ideal conditions for tumor growth. Thus, a model of parallel tumor-promoting changes within an evolving cancer organ, rather than the strict clonal evolution of the tumor cell suggested by earlier models of cancer evolution, most accurately represents current data (Figure 1) . Clearly, in the case of the Yang et al. study, causal changes in the microenvironment were engineered in the mice and already existed in the neurofibromatosis patient (which is likely to also be the case for other familial disorders). It will be more challenging, but of significant importance, to determine the extent to which stromal changes are causal in sporadic tumorigenesis.
The concept of cancer as an evolving organ has implications for developing therapeutic approaches. Taking advantage of the mast cell dependence on c-kit activity, Yang and colleagues asked whether imatinib mesylate, a potent inhibitor of c-kit, could be used to treat neurofibromas. Remarkably, not only did administration of the compound decrease neurofibromas in a mouse model of neurofibromatosis, but it was also able to shrink a neurofibroma in a 3-year-old human patient. Subsequent clinical trials will determine the robustness and stability of the response to imatinib mesylate treatment. Yang et al.'s elegant use of genetic engineering to block the c-kit receptor specifically in stromal cells shows that the state of the cancer stroma may be as important a factor in therapy development as the state of the tumor cells themselves. The current use of immunocompromised xenograft mouse models to develop cancer therapies has been only minimally predictive of therapeutic efficacy in patients. This may be in part due to inappropriate microenvironments for tumor growth, as in the case of the widely used subcutaneous xenograft mouse model. The weakness of this model system may reflect the naive state of the stroma, which has not been subjected to the same selective pressure as the tumor stroma in patients. Greater understanding of the tumor microenvironment and its relationship to normal stroma will aid the development of better tools for testing therapeutics and will highlight new therapeutic targets. In this regard, genetically engineered mouse models of human cancers have the advantage that cancer cells can coevolve with the surrounding stroma, enabling recapitulation of the "highly integrated ecosystem" of the cancer organ.
Human cancer cells tend to be genetically unstable and develop new genomic aberrations over time. However, it is less clear whether benign tumors such as neurofibromas or stromal cells including mast cells share this capacity to mutate, as they could be subject to greater cell cycle and DNA damage control. One of the difficulties in the use of imatinib mesylate for the treatment of cancer has been the development of resistance to this tyrosine kinase inhibitor through the acquisition of mutations in the targeted kinases. The hope is that stromal cells may be less likely than their associated tumor cells to develop drug resistance over a patient's lifetime. The Yang et al. study describes a single, albeit convincing, case report of successful treatment of a neurofibromatosis patient with imatinib mesylate. It will be important to see how widely applicable this treatment is (particularly in terms of neurofibromatosis), whether continuous drug administration is required to suppress the stromal contribution to tumorigenesis, and whether drug resistance becomes an issue after longterm use.
Nearly four decades ago, studies of the rare genetic disease retinoblastoma led to a new understanding of how tumors develop mutations and of the role of tumor suppressor genes in tumorigenesis (Knudson, 1971) . Now, studies of the familial disorder neurofibromatosis, such as that of Yang et al., are confirming the complexity of cellular interactions within tumors and demonstrating the vulnerabilities of these interactions to therapeutic intervention. In Bacillus bacteria, the process of sporulation is triggered by nutrient starvation, and the resulting spores are metabolically dormant and extremely resistant to a variety of stress factors (Setlow, 2006) . As a consequence, spores can survive for long periods of time, certainly for hundreds of years if not more. However, even though these spores are dormant, they are continually monitoring their environment, and if conditions favorable for cell growth return, the spores can rapidly break dormancy and "return to life" (Setlow, 2003) . In the current model for spore germination, specific nutrient molecules bind to their cognate germinant receptors located in the inner spore membrane ( Figure 1A ). This leads to the release of small molecules from the spore core, most notably the huge depot of dipicolinic acid chelated 1:1 with divalent cations, largely Ca 2+ (Ca-DPA), and replacement of these small molecules by water. In the dormant spore core, water is maintained at an extremely low level, likely to prevent enzymatic activity. The release of Ca-DPA activates enzymes that can degrade the spore's peptidoglycan cortex restricting the swelling of the spore core. Hydrolysis of the cortex leads to the swelling of the spore core and further water uptake ( Figure 1B ). The water content is then high enough to allow enzyme action, metabolism, and macromolecular synthesis, with vegetative growth following soon thereafter.
In this issue, Shah et al. (2008) report evidence for an alternative and very different mechanism for initiating germination, based largely on work with the model organism and spore former Bacillus subtilis, a species of Grampositive bacteria. They find that germination of B. subtilis spores, as well as those of several other Bacillus species, can be triggered by extremely low concentrations (≤1 pg/ml) of muropeptides, which are produced by degradation of the peptidoglycan that comprises the cell wall of most bacteria. Such degradation is a normal feature of bacterial cell growth. In growing Gram-negative bacteria, muropeptides are not generally released in significant amounts due in large part to efficient recycling, whereas Gram-positive bacteria recycle muropeptides poorly (Doyle et al., 1988; Mauck et al., 1971) . As a consequence, high levels of muropeptides in the environment could indicate abundant growth of Gram-positive bacteria and thus provide a logical environmental signal that could initiate spore germination. The muropeptide signal leading to B. subtilis spore germination is not just from any muropeptide but only from those that have the amino acid meso-diaminopimelate (Dpm) at position three of the stem peptide linked to the muropeptide's oligosaccharide backbone. Dpm is the amino acid found in this position in peptidoglycan of growing B. subtilis cells. In contrast, the peptidoglycan from at least one other Bacillus species, B. sphaericus, and other Gram-positive bacteria such as Staphylococcus aureus contain L-lysine in the third position of the stem peptide (Hungerer and Tipper, 1969; Schleifer and Kandler, 1972) , and muropeptides from this type of peptidoglycan are ineffective at eliciting B. subtilis spore germination.
Notably, the triggering of spore germination by the appropriate muropeptides occurs in the absence of all nutrient germinant receptors, suggesting that muropeptides do not trigger germination through the nutrient germinant receptors. As a consequence, Shah et al. (2008) 
